Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin

Citation: Flores-Cordero, J.A.; Pérez-Pérez, A.; Jiménez-Cortegana, C.; Alba, G.; Flores-Barragán, A.; Sánchez-Margalet, V. Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin. Int. J. Mol. Sci. 2022,23, 5202. https://doi.org/10.3390/ijms23095202 Academic Editor: Jean-François Tanti Received: 28 March 2022 Accepted: 4 May 2022 Published: 6 May 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). International Journal of Molecular Sciences Review Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin Juan Antonio Flores-Cordero , Antonio Pérez-Pérez , Carlos Jiménez-Cortegana , Gonzalo Alba, Alfonso Flores-Barragán and Víctor Sánchez-Margalet * Department of Medical Biochemistry and Molecular Biology and Immunology, Medical School, Virgen Macarena University Hospital, University of Seville, Av. Sánchez Pizjuan 4, 41009 Sevilla, Spain; [email protected] (J.A.F.-C.); [email protected] (A.P.-P.); [email protected] (C.J.-C.); [email protected] (G.A.); [email protected] (A.F.-B.) *Correspondence: mar[email protected] Abstract: Obesity is a growing worldwide health problem, affecting many people due to excessive saturated fat consumption, lack of exercise, or a sedentary lifestyle. Leptin is an adipokine secreted by adipose tissue that increases in obesity and has central actions not only at the hypothalamic level but also in other regions and nuclei of the central nervous system (CNS) such as the cerebral cortex and hippocampus. These regions express the long form of leptin receptor LepRb, which is the unique leptin receptor capable of transmitting complete leptin signaling, and are the first regions to be affected by chronic neurocognitive deficits, such as mild cognitive impairment (MCI) and Alzheimer’s Disease (AD). In this review, we discuss different leptin resistance mechanisms that could be implicated in increasing the risk of developing AD, as leptin resistance is frequently associated with obesity, which is a chronic low-grade inflammatory state, and obesity is considered a risk factor for AD. Key players of leptin resistance are SOCS3, PTP1B, and TCPTP whose signalling is related to inflammation and could be worsened in AD. However, some data are controversial, and it is necessary to further investigate the underlying mechanisms of the AD-causing pathological processes and how altered leptin signalling affects such processes. Keywords: obesity; leptin; inflammation; leptin resistance; Alzheimer’s disease 1. Introduction When focusing on dementia, it is worth noting that the separating line between normal and pathological aging is not adequately defined. Therefore, it is difficult to determine where each phenomenon begins and ends and to distinguish the common deficiencies and individual differences within these phenomena [ 1 ]. This narrow line that separates the normal from the pathological is where we must intervene to minimise the symptoms the disease produces, making an early diagnosis of dementia necessary. The difficulty is even greater taking into account that the aging process itself can produce negative effects on general health and cognitive function in particular. Similarly, aging is linked to an increase in body weight, adiposity, and variations in hormones and adipokines, showing an altered pattern with age [ 2 , 3 ]. Similarly, both in murine and human models, an increase in microglial reactivity and inflammation with age has been described [ 2 , 3 ]. In this review, we discuss how this altered pattern is a factor that predisposes to obesity and dementia, such as Alzheimer’s disease (AD). Procedures have been developed over time to identify patients with early onset dementia, a concept that has evolved into the current term, mild cognitive impairment (MCI). Ronald Petersen developed the concept of MCI through the Mayo Clinic. The concept was an improvement in its attempt to identify people who may progress to dementia, as the cognitive aspects were introduced to the pre-existing aspects of memory. Currently, the fundamental objective of dementia research is to find markers that provide an early Int. J. Mol. Sci. 2022,23, 5202. https://doi.org/10.3390/ijms23095202 https://www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2022,23, 5202 2 of 22 diagnosis and thus enable action to be taken before the disease evolves [ 1 ]. MCI is an example of this. Today, obesity is growing in the global population due to multiple causes: lifestyle, stress, nutrition, genetic background, and lack of exercise. In obesity, white adipose tissue (WAT) not only stores excess energy but also disturbs endocrine function. WAT secretes a group of substances called adipokines that exert autocrine, paracrine, and endocrine effects at the systemic level and also centrally in the central nervous system (CNS) [ 4 – 6 ]. Obesity has been linked to cognitive deficits, impaired long-term potentiation and synaptic plasticity, and a smaller brain volume, increasing the probability of developing Alzheimer’s disease (AD) and other dementias [ 7 ]. Thus, obesity is established as a risk factor for dementia. Furthermore, obesity causes a state of low-grade chronic inflammation in adipose tissue that leads to the dysregulation of homeostatic systems, which in turn leads to the development of various diseases, including those related to neurodegeneration. During this process, adipose tissue produces an increase in pro-inflammatory adipokine levels (interleukin 1 beta (IL-1 β ), interleukin 6 (IL-6), and tumoural necrosis factor alfa (TNF- α ), and leptin) and a decrease in anti-inflammatory adipokine levels, such as adiponectin [ 4 , 6 ]. Yet another essential component of these complex interrelationships between obesity and brain status is the gut microbiota. In fact, meticulously detailed in a review by authors [ 8 ], it is explained how an altered intestinal microbiota pattern (or dysbiosis) can lead to a permanently altered physiological pattern, which can lead to cognitive impairments due to alterations in the gut-brain axis. In addition, it indicated that the administration of pre- and probiotics can restore this dysbiosis, enabling a return to an adequate homeostatic balance. Leptin, a pro-inflammatory adipokine secreted by WAT and found to be increased in people with a high body mass index, acts centrally at the level of the hypothalamic region through anorexigenic proopiomelanocortin (POMC)/cocaine- and amphetamine-regulated transcript (CART) neurons and orexigenic neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons, controlling food intake and energy expenditure. The literature suggests that leptin may be the link between obesity and dementia through the development of inflammation. Therefore, we will analyse the information on inflammation-induced leptin resistance that occurs during obesity as a pathological mechanism that may underlie neurodegenerative diseases such as AD and other dementias. 2. Obesity and Dementia Obese individuals are at greater risk of developing age-related cognitive decline, vascular dementia, MCI, and AD [ 4 ], as well as other neurodegenerative pathologies such as Parkinson’s [ 9 , 10 ] and Huntington’s disease [ 10 , 11 ]. In this section, we give an overview of obesity as a risk factor for dementia based on adipose tissue measurement indices, brain structural changes, and cognitive impairment measurements. Our purpose is to identify modifiable risk factors that allow an early diagnosis and treatment. Obesity can be defined as an excessive accumulation of adipose tissue which generates a low-grade inflammation state, whereas AD can be defined as a progressive neurodegenerative disease whose distinctive histopathological characteristics are the extracellular amyloid plaques and intracellular neurofibrillary tangles. A parameter used as a measure of adiposity is the body mass index (BMI). However, its use has not been free from difficulties. That is why the waist circumference and the waist-to-hip ratio (WHR) have also been used to evaluate excess fat [ 12 ]. In fact, in the work by Beyer et al. (2019) [ 12 ], it is suggested that the WHR, as part of a metabolic obesity profile, is a determining factor that plays a role in grey matter volume reductions, which might lead to reduced cognitive functions, that have a weaker association when using the BMI [ 12 , 13 ]. Nevertheless, BMI is the most widely used adiposity index [ 14 – 16 ]. Thus, an association between BMI and dementia has been described, although this relation is controversial [ 14 – 17 ]. Firstly, it has been suggested that being overweight and obese in middle age is related to a higher risk of dementia in old age. Nevertheless, a high BMI in late life is associated with better cognition [ 6 , 16 , 17 ]. Secondly, other studies have described Int. J. Mol. Sci. 2022,23, 5202 3 of 22 contradictory outcomes, where a lower risk of dementia was observed for very obese people (BMI > 40 kg/m 2 ) while underweight people (BMI < 20 kg/m 2 ) display a higher dementia risk than heavyweight people [ 18 ]. There are different epidemiological studies that relate obesity and dementias, such as the more frequent AD, but, in general, these studies find a positive correlation between obesity and cognitive impairment, with a possible U-shaped curve. In this context, a reverse relation has been described between obesity and grey matter and whole brain volume [ 19 – 25 ], even though a minor number of publications did not find such a relation [26,27]. As mentioned above, obesity generates a chronic low-grade inflammation state, which is characteristic of a variety of other chronic conditions, such as metabolic syndrome, nonalcoholic fatty liver disease, type 2 diabetes mellitus, and cardiovascular disease [ 28 , 29 ], as well as neuroinflammation [ 30 – 32 ], a hallmark of neurodegenerative diseases such as AD [ 33 – 35 ]. Following this line, different animal studies have confirmed the connection between obesity and cognitive mismatches and/or impairment. Thus, different works point to an altered cognitive function when administering a less-healthy diet. A highfat diet (HFD) rich in saturated fatty acids can result in obesity as well as deficits in hippocampal-dependent learning and memory functions [ 36 , 37 ]. Male Wistar rats fed with a HFD showed impaired memory, an effect that was augmented with a longer duration of HFD consumption [ 38 ] while, similarly, rats fed with a high-fructose-high-coconut oil diet experienced impaired hippocampal-dependent learning and memory processes, as evaluated through the Morris water maze task [ 39 ]. In another study [ 40 ], HFD-induced brain insulin resistance and cognitive impairment were observed. Molecular changes, such as a significant decrease in tyrosine phosphorylation of the insulin receptor and increased serine phosphorylation of IRS-1, which are signs of insulin resistance, might be the cause of the cognitive impairment in this mouse model. These molecular changes were accompanied by inflammatory signalling (NF κ B, JNK) and stress responses (p38 MAPK, CHOP) in whole brain lysate. In a transgenic rat model of pre-AD and MCI, impaired special learning and memory has been described in the Morris water maze when rats received a high-caloric diet [ 41 ]; at the same time, some parameters of brain inflammation, such as microgliosis, were also found. Moreover, activated OX-6+ microglia were detected, as well as GFAP+ astrocytes located predominantly in the white matter, and the synaptic density in the CA1 and CA3 hippocampal subregions was lower in this high-calorific diet. In a triple transgenic AD mice model (3xTg-AD), an impairment in the cognitive function has been shown when administering a HFD, and this diet was able to induce enhanced oxidative stress and aggravated neuronal apoptosis via inactivation of the Nrf2 signalling pathway [ 42 ]. So, numerous animal studies indicate the relation between obesity and AD and other forms of dementia that affect cognitive function. Overall, obesity seems to be a risk factor for different forms of dementia, where we can find long-term memory and attention impairment, and executive function deficits. We have reviewed how cerebral structural and functional changes in obese people occur, and how a high saturated fat diet can affect cognitive function, including brain inflammation as a hallmark of this process. 3. Obesity and Leptin Energy homeostasis and the maintenance of body weight require that the peptides secreted by the organs of the periphery establish a signalling and functional interrelation between them. To do this, adipocytes synthesise and secrete adipokines with pleiotropic effects in various tissues and regulate numerous physiological functions [ 43 , 44 ]. In this review, we will focus on leptin, due to its involvement in the regulation of food intake and energy expenditure, studying its involvement in dementia and its relationship with obesity. Leptin has been found to circulate in plasma in proportion to body fat mass and this can be taken as an indicator of adiposity [ 45 , 46 ]. However, its study is difficult, since its levels vary by multiple factors: sex, BMI, starvation, and energy states. In addition, it shows a circadian rhythm, with leptin levels at their maximum between midnight and Int. J. Mol. Sci. 2022,23, 5202 4 of 22 dawn, and is affected by other hormones and cytokines [ 47 ]. Leptin is a 16 kilodalton (kDa) peptide hormone produced by the ob (obese) gene. Leptin receptors are class I cytokine receptors. Previous studies have described six isoforms of the mRNA variants of the gene encoding the leptin receptor: four short forms (LepRa, LepRc, LepRd, LepRf), one long form (LepRb), and an extracellularly secreted soluble form (LepRe) [ 48 ]. Furthermore, five of the six isoforms (LepRa-LepRd and LepRf) have common extracellular and transmembrane domains, and only the soluble form (LepRe) has only an extracellular domain [ 48 ]. The long form LepRb has intracellular domains and proline-rich regions known as box1, box2, and box3 that are associated with Janus kinase (JAK) and signal transducer activators of transcription (STAT) signalling activation, whereas the other isoforms seem to be implicated in the leptin transport from the periphery to the CNS through the blood-brain-barrier (BBB) [ 48 – 52 ]. Leptin receptors are expressed throughout the body. In the CNS, leptin receptors are expressed in the arcuate nucleus (ARC), the dorsomedial hypothalamus (DMH), the ventromedial hypothalamus (VMH), the lateral hypothalamus (LH), the mediobasal hypothalamus (MBH), and the paraventricular nucleus (PVN). In addition, they have also been found in the cerebral cortex, hippocampus, ventral tegmental area, substantia nigra, medulla, and cerebellum [ 48 , 50 , 52 – 57 ]. Furthermore, the short isoforms LepRa and LepRc are expressed in the brain microvessels that make up the BBB, suggesting that these receptors may be associated with leptin transport [ 53 , 54 ]; in fact, the LepRa and LepRc isoforms have been shown to mediate leptin transport in the BBB, and dysfunctional receptors can lead to leptin resistance [ 56 ]. The expression of the leptin receptor has been observed in different neurons, including glutamatergic, GABAergic, and dopaminergic neurons. Thus, there is evidence of its involvement in the mechanisms of long-term potentiation, long-term depression, and motivational eating [42,44,45,48,49]. Biochemically, when leptin binds to its receptor it allows the activation of Janus kinase 2 (JAK2) and its autophosphorylation. Once activated, JAK2 phosphorylates other tyrosine residues (Tyr) in the receptor, including Tyr985, Tyr1077, and Tyr1138, to mediate different intracellular signalling pathways [48,58,59]. Intracellular signalling pathways initiated by the leptin receptor are [48,53,58,60,61]: 1. JAK/signal transducer activators of transcription 3 (STAT3); 2. Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt); 3. Extracellular signalling-regulated kinases (ERK); and 4. Signal transducer activators of transcription 5 (STAT5). As we will see below, leptin is involved in various aspects of cognition, neurogenesis, neuroprotection, synaptic plasticity, and structural changes [ 57 , 62 ], which is not surprising given its access from the periphery to the CNS, the number of leptin receptors, and its wide distribution in the brain. 4. Leptin; Its Relationship with Cognition and Synaptic Function An important aspect of dementia is cognitive deterioration, which is manifested in different aspects such as synaptic function, learning, and memory. So, before addressing the connection between leptin and dementia, it is important to analyse the relationship and implication of leptin with these different aspects of cognition. Leptin signalling regulates different processes including food intake, energy expenditure, cognition, learning, memory, and mood [ 63 ]. Studies show that leptin performs different neuroprotective functions [ 56 , 57 , 63 – 65 ]. Furthermore, leptin regulates neurogenesis, synaptogenesis, neuronal excitability, and neuroprotection [57,62]. In learning and memory processes, synaptic plasticity, and the relationships between neurons at the level of synaptic transmission, are fundamental. Furthermore, in these processes, the mechanisms of long-term potentiation (LTP) and long-term depression (LTD) of synaptic transmission are crucial for the formation and consolidation of hippocampal memory. Thus, leptin is involved in these processes at the level of the hippocampus where leptin and glutamate receptors {N-methyl D-aspartate (NMDA) and α -amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid (AMPA) receptors} are key players [ 4 , 50 , 59 ]. In support Int. J. Mol. Sci. 2022,23, 5202 5 of 22 of this evidence, leptin receptors have been found in neuronal and non-neuronal cells in the hypothalamus, the cerebral cortex, as well as in the dentate gyrus, and the CA1 and CA3 areas of the hippocampus [ 62 ]. This last finding is fundamental, as these areas are highly involved with cognition and memory. Recent studies indicate that NMDA receptors are necessarily involved in leptin-dependent homeostatic control of body weight [ 66 ]. Thus, leptin enhances NMDA receptor function by promoting the efficiency of excitatory synaptic transmission at hippocampal Schaffer-collateral (SC)-CA1 synapses and allowing the conversion of short-term potentiation into LTP. Therefore, it is not surprising to have found LTP and LTD deficiencies in leptin-insensitive obese mice (db/db) and rats deficient in the leptin receptor (fa/fa) [ 4 , 59 ]. Consequently, leptin improves hippocampaldependent memory. Thus, in the review by McGregor and Harvey [ 66 ] it is found that in transgenic mouse models of Alzheimer’s disease (CRND8), leptin improved performance in object recognition, contextual, and fear-conditioned tasks. In addition, performance in hippocampal-dependent memory tasks was also optimised in mice prone to accelerated senescence (SAMP8) that have elevated levels of the β-amyloid peptide (Aβ). Leptin can also regulate the configuration of neurons. Thus, plasma leptin levels have been associated with grey matter volume in various brain regions. Exogenous leptin administration recovers structural brain abnormalities in congenitally leptin-deficient humans and reverses the abnormalities in ob/ob mice [ 62 ]. Interestingly, the study by Annweiler [ 64 ] finds a relationship between circulating leptin levels and U-shaped cognition. Their results suggest that older adults with low or high circulating leptin concentrations are particularly prone to cognitive impairment and point to leptin as a modifiable risk factor. Therefore, we can say that leptin, through its actions in the periphery or the CNS, produces neuroprotective effects that improve cognitive function and memory. As a result, its dysfunction due to a deficit in signalling pathways, a decrease or alteration of its levels, or leptin resistance can cause processes that promote neurodegeneration [62]. 5. Leptin Resistance: Mechanisms Involved Leptin is reduced during fasting and increases with food consumption. When we eat, adipocytes release leptin, which tends to reduce eating behaviour. However, the paradox exists that in obesity, the leptin levels are increased; despite this, there is no indication or signal of satiety due to a peripheral and/or central resistance to leptin. Thus, an imbalance between anorexigenic and orexigenic signals occurs, which leads us to receive a signal of decreased satiety, and contributes to obesity, leading to a vicious cycle [4,61]. Resistance to leptin indicates that despite high plasma levels in obese people, signalling in the hypothalamus is decreased [ 4 ]. The foregoing leads us to review and analyse the factors involved in this dysfunction in leptin signalling. Next, we analyse the mechanisms that have been proposed as an explanation for leptin resistance, which is related to obesity, and helps to develop or perpetuate diseases such as dementia: (a) genetic mutations, (b) alterations in the transport of leptin through the BBB, (c) desensitisation of leptin receptors that reduce the functionally active number, (d) attenuation of signalling leptin {suppressor of cytokine signalling type 3 (SOCS3), protein tyrosine phosphatase type 1B (PTP-1B), and protein tyrosine phosphatase of T cells (TCPTP)}, (e) alteration of cellular descending leptin signalling in the CNS, and (f) multiple factors such as inflammation, elevated levels of C-reactive protein (CRP), adapter protein1 (SH2B1), and endoplasmic reticulum (ER) stress as well as decreased activity of histone deacetylase and the type of diet [ 58 , 61 , 67 – 70 ]. In this context, obesity-related inflammation may contribute to leptin resistance, which in turn further increases weight gain [ 71 ] and leptin levels, which then increases the inflammationrelated obesity, since leptin is an important proinflammatory adipokine [ 72 – 74 ], activating monocytes [75] and lymphocytes [76]. 5.1. Pathways of Leptin Entry into the Brain and Leptin Resistance There are several pathways for the entry of leptin into the brain: through the (a) endothelial cells of the BBB, (b) epithelial cells of the choroid plexus, and (c) through the Int. J. Mol. Sci. 2022,23, 5202 6 of 22 medio basal hypothalamus, which is surrounded by tanicytes that form a barrier between the median eminence and the cerebrospinal fluid [ 77 – 79 ]. Existing evidence shows that leptin traverses the BBB through a saturable transport system, but there are doubts about the involvement of LepRa [ 51 , 52 , 61 , 77 ]. An investigation has found that brain endothelial cells express higher levels of LepRa than LepRb or megalin receptor 2 (Lrp2). Furthermore, leptin has a higher affinity for both LepRa and LepRb, suggesting that LepRs are the most important binding sites for leptin, rather than Lrp2 [ 79 ]. Likewise, in another report, it has been suggested that the leptin receptor is necessary in the brain barrier for the uptake of leptin by the brain and the regulation of the food reward; megalin receptor 1 (Lrp1) and Lrp2 are considered alternative transporters [ 77 ]. However, the work by Bartolome et al. [ 80 ] provides evidence against the leptin receptor. Here, it has been suggested that LepR is not the main leptin transporter in human BBB, but rather the megalin receptor, since the authors observed a reduction in brain leptin uptake by eliminating the megalin receptor in the endothelial cells of the BBB, which induced hyperphagia and obesity. In the literature, there are two contradictory currents of thought as to whether the leptin resistance at the level of the BBB is due to a deficient leptin transport. On the one hand, there are studies that support the idea that there is a decrease in leptin transport through the BBB. In this sense, circulating factors in the blood, such as triglycerides, could reversibly inhibit leptin transport. Thus, low levels of these factors allow the transport of leptin through the BBB, but high triglyceride doses can inhibit it. Therefore, treating triglyceride levels in the blood could decrease central (and peripheral) resistance to leptin and reduce obesity and the cognitive problems associated with it [ 4 , 78 , 81 ]. This idea is also supported by Di Spiezio [ 77 ] who states that a deficit in the transport of leptin to the brain can increase the food reward. Furthermore, obese rodents have been shown to respond to the central administration of leptin through intracerebroventricular injections, but not to peripheral administration of leptin through intraperitoneal injections, which may be indicative of a possible impairment in transport through the BBB [ 68 , 81 ]. On the other hand, it has also been hypothesised that there is no deficit in the transport of leptin through the BBB. In this sense, it has been found that obese mice, as well as lean mice, retain a functional leptin transport system without leptin deficiency in the circumventricular organs, with the choroid plexus and the mediobasal hypothalamus playing a key role [ 67 ]. Another finding that supports the idea that there is no deficient transport of leptin through the BBB is that of the Bardet-Biedl Syndrome (BBS) mouse model, characterised by retinal dystrophy, polydactyly, renal and gonadal anomalies, cognitive impairment, and obesity, and, where proteins of an octameric complex, the “BBSome”, are mutated, leading to impaired transport of the leptin receptor LepRb to the plasma membrane in hypothalamic cells, thereby preventing intracellular signalling which causes resistance to leptin and obesity [82]. These contradictory results warrant further investigation in order to clarify the role of leptin transport through the BBB in leptin resistance. 5.2. Inflammation and Leptin Resistance It has been suggested that leptin resistance in obesity might start through the activation of inflammatory signalling [ 69 ]. It is generally accepted that, in obesity, hypertrophic adipocytes suffer an increase in proinflammatory cytokines expression and secretion that have periphery and brain effects [ 83 , 84 ]. Furthermore, several adipokines, and interleukins, in particular, are associated with the inflammatory processes implicated in dementia [ 6 , 83 ]. The production of interleukin 6 (IL-6), which is triggered by a lack of exercise and by saturated fat-rich diets, can lead to resistance to anorexigenic signals in the hypothalamus [ 52 ]. Low-grade inflammation due to obesity drives human C-reactive protein (CRP) production by hepatocytes in vitro and in vivo in humans [ 85 ]. It has been found that peripheral human CRP can reduce the amount of human leptin that enters the CNS, preventing its transport across the BBB and into the median eminence. Furthermore, once inside the CNS, it reduces the physiological function of human leptin [ 85 ]. So, both mechanisms may Int. J. Mol. Sci. 2022,23, 5202 7 of 22 contribute to leptin resistance. Therefore, we can consider CRP a mechanism involved in inflammation-mediated leptin resistance. Inflammation causes central resistance to leptin through the expression of SOCS3. Thus, it has been found that SOCS3-stimulated adipocyte apoptosis worsens inflammation and inhibits the activity of the JAK2/STAT3 signalling pathway [86]. Many advances have been made through studies seeking to ameliorate obesity and hyperphagia produced by diets high in fatty acids. Interestingly, positive results in these studies have involved reduced inflammation and/or increased leptin sensitivity. As evidence of the above, it has been found that the peripheral delivery of the interleukin 10 (IL-10) gene using an adeno-associated virus (AAV) is capable of suppressing inflammation in the hypothalamus arcuate nucleus (ARC) in mice with diet-induced obesity (DIO) and decreasing hyperphagia and obesity [ 87 ]. Another study finds that proinflammatory cytokines in the brain increased Toll-like receptor 4 (TLR4) expression, ER stress, and nuclear factor kappa light chain enhancer of activated B cells (NF-kB) expression. Furthermore, this led to increased inflammation and leptin resistance, which was reduced by treatment with pyrogallol-phloroglucinol-6,6-bieckol (PPB) [ 84 ]. The central administration of docosahexaenoic acid (DHA, 22:6 n-3) reduced high-fat diet (HFD)-induced inflammation and obtained beneficial effects by inhibiting SOCS3 [ 88 ]. It has been found that the use of the plant terpenoid compound ginsenoside Rb1 reduces body weight gain, the accumulation of fat mass, and the expression of inflammatory markers, SOCS3 and PTP1B, in addition to reducing the deterioration of the signalling pathway JAK2-STAT3 and central leptin sensitivity due to obesity induced by high fatty acid diets [89,90]. Taken together, these studies suggest that neuroinflammation could cause leptin resistance, so acting on inflammation may be a way to reduce leptin resistance. In support of this, it is worth noting that a study related to inflammation and the signalling pathway of NF-KB mediated by sirtuins (SIRT) shows that its regulation can play an important role in neuroinflammation, as well as in local inflammation [ 91 ]. In addition, the NF-kB factor appears to play an important role in hypothalamic leptin resistance [92]. In summary, the data suggest that a HFD may reduce leptin sensitivity and that obesity may induce inflammatory processes. Furthermore, the studies and the scientific evidence presented seem to indicate that reducing inflammation can act on the pathways involved in leptin resistance, producing an improvement in leptin or its sensitivity [ 92 ] and obtaining favourable results on obesity. Likewise, SOCS-3 is hinted at as a mechanism mediating leptin resistance. 5.3. Hypothalamic Endoplasmic Reticulum Stress and Leptin Resistance Endoplasmic reticulum (ER) stress is currently being implicated as a mechanism that can lead to leptin resistance [ 93 ]. Thus, early exposure to stress has been found to alter factors in the adipose tissue and leptin system that led to increased body fat accumulation when exposed to a western diet later in life [ 5 ]. An aldehyde, 4-hydroxy-2-nonenal (4- HNE), may be involved in the development of leptin resistance in neuronal cells. Levels of this aldehyde can rise with fat accumulation which can initiate an ER stress response and further increase its production, and can then lead to impaired leptin signalling and obesity [ 94 ]. The elevated free fatty acid concentration in the hypothalamus can lead to lipotoxicity. Furthermore, a relationship between hypothalamic lipotoxicity and ER stress has been suggested as a possible explanation for the onset of obesity [95]. Alternatively, various compounds with the ability to decrease ER stress and/or ER stress-induced leptin resistance have been reported [ 93 ]. Notably, fluvoxamine has the ability to reduce ER stress through the sigma-1 receptor (Sig-1R) and its effect on reducing leptin resistance may be due to this mechanism. Celastrol, a chemical chaperone, ameliorates hypothalamic ER stress and obesity in mouse models. Chemical chaperones are compounds that have been suggested to diminish ER stress-induced leptin resistance. Flurbiprofen has also been found to improve ER stress-induced leptin resistance and HFD-induced obesity. Collectively, the above information allows us to affirm that certain compounds Int. J. Mol. Sci. 2022,23, 5202 8 of 22 favour ER stress and increase leptin resistance while others decrease it and improve leptin resistance [ 93 ]. Therefore, future research should focus on investigating the pathways through which these compounds carry out their beneficial or detrimental effects. Lipotoxicity has been linked to ER stress and the downstream melanocortin system, in that the suppression of mitofusin2 (Mfn2) in proopiomelanocortin (POMC) neurons causes stress in the ER, thus altering the processing of melanocyte-stimulating hormone ( α - MSH) and causing leptin resistance and obesity. Therefore, administration of the chemical chaperone 4-phenylbutyrate (4-PBA) was able to correct the tendency of the endogenous melanocortin 4 receptor (MC4R) to fold incorrectly and restore the correct response of α-MSH [95]. Sleep fragmentation has also been linked to hypothalamic ER stress. Specifically, the former induces the latter, leading to hyperphagia and leptin resistance. What is significant in this study is the observation of an increase in PTP1B expression and activity due to sleep fragmentation. The authors conclude that while sleep fragmentation seems to induce leptin resistance through PTP1B, high-calorie diets would induce it through SOCS3. However, this situation is reversed with a chemical chaperone treatment or with transgenic ablation of CHOP-/+ [ 96 ]. Therefore, the PTP1B and SOCS3 negative feedback pathways seem to affect leptin resistance; specifically, the PTP1B pathway would be affected by hypothalamic ER stress and the SOCS3 pathway would be affected by high-calorie diets. Finally, we can point out that ER stress induces leptin resistance. Furthermore, the POMC hypothalamic neurons of the arcuate nucleus are vulnerable to ER stress [ 95 ] and leptin exerts its effects through them. Therefore, we accept the implication of ER stress in leptin resistance, but it is possible that this is due to the interaction or combination of some of the different mechanisms which induce it. 5.4. Reduced Sensitivity to Leptin (Receptors, Receptor Downstream Signaling, and Negative Feedback Signaling Pathways) Certain intracellular factors such as SOCS3, PTP1B, and TCPTP negatively control leptin signalling and may be involved in leptin resistance [ 92 ]. Thus, the elimination or attenuation of SOCS3 expression produces beneficial effects on leptin sensitivity and resistance; however, its increased expression is detrimental [ 97 – 100 ]. Evidence has been given of mice with neuronal SOCS3 or PTP1B deficiency that have improved sensitivity to leptin and insulin, and are resistant to increases in body weight when exposed to high-fat diets [ 92 ]. Animal models with suppression or precise variations of SOSC3 have shown greater sensitivity to leptin, in addition to showing resistance to DIO, weight loss, and decreased food intake [ 68 ]. In a study using risperidone in the human neuroblastoma cell line (SH-SY5Y), the authors found increases in both SOSC3 and suppressor of cytokine signalling type 6 (SOCS6) proteins through the cyclic adenosine monophosphate/protein kinase A/ERK pathway (cAMP/PKA/ERK); the drug causes excessive weight gain due to inhibition of leptin and insulin signalling pathways [ 101 ]. In a fasting-induced hyperphagia assay, mice lacking the SOCS3 protein in LepR-expressing cells (LepR SOCS3KO) showed increased leptin sensitivity in the hypothalamus, and hyperleptinemia was also prevented [ 98 ]. Furthermore, one paper finds that leucine supplementation improves leptin sensitivity in HFD rats by promoting leptin signalling and downregulating SOCS3 expression [97]. An interesting assay involving the orexigenic hormone ghrelin shows a significant increase in exchange protein activated by cAMP (Epac) and SOCS3 in cultured rat nodose ganglia (NG) neurons that significantly inhibits the anorexigenic hormone leptin-induced STAT3 phosphorylation. From the study, the authors conclude that the SOCS3 signalling pathway plays a fundamental role in the inhibitory effect of ghrelin on leptin-induced STAT3 phosphorylation [ 100 ]. Other works conclude that the deregulation of SOCS3 expression and activity may be involved in leptin resistance by interrupting the negative feedback loop [ 70 , 99 ]. However, Pedroso et al. [ 99 ] indicate in their report that the mechanism involved in the inhibition of SOCS3 in LepRb-expressing cells could depend on specific Int. J. Mol. Sci. 2022,23, 5202 9 of 22 neurons, finding that it cannot prevent diet-induced obesity. Therefore, we conclude that the alteration of the negative feedback pathway SOCS3 could somehow be involved in leptin resistance. Specific inhibitors for SOCS3 have not been developed [ 70 ], although they may be an option to restore the leptin response. A limitation in their development is the need to act specifically on the neuronal circuits involved in the regulation of body weight since its inhibition can cause serious alterations. Some suggested pharmacological strategies for SOCS3 inhibition are microRNA therapy and administration of zoledronic acid [ 102 ]. Inhibition has also been suggested with a specific strategy at the level of the leptin receptor pathway [ 70 ]. Furthermore, following a study in which it was discovered that the inhibition of the cell cycle checkpoint protein Ataxia Telangiectasia and RAD3-related protein (ATR) leads to a decrease in the expression of SOCS3, the use of ATR inhibitors in the development of new treatments for obesity may be useful [103]. Additionally, we will review some works that implicate the increased expression of the negative regulatory molecules PTP1B and TCPTP in leptin resistance. Thus, PTP1B has been linked to central leptin resistance in humans and in a variety of animal models of obesity and aging [ 4 ]. Similarly, in a study using the intranasal route of administration, suppression of PTP1B/TCPTP in the ARC was shown to restore downstream leptin responses. They also suggest that the combined deletion of PTP1B and TCPTP in the ARC of obese mice may produce synergistic effects that contribute to decreased food intake and weight loss. Conversely, in the aforementioned report, it is shown that the removal of SOCS-3 did not have an additional impact on body weight [ 104 ]. In another study, the authors found that hypothalamic suppression of PTP1B and LepRb failed to rescue hyperphagia or obesity in mice deficient in PTP1B and LepRb [Nkx2.1-LepRb(-/-)]. Thus, they suggest that functional leptin receptor signalling is in fact required for the metabolic effects of PTP1B. Likewise, they propose two models: the first where PTP1B deficiency exerts beneficial effects because of increased sensitivity to leptin, and a second model in which the consequences of PTP1B deficiency are achieved through the combination of different signalling pathways, where leptin plays a fundamental role [ 105 ]. Furthermore, we can suggest that additional signalling pathways in the brain may contribute to the metabolic effects produced by inhibiting PTP1B. Thus, another study shows that PTP1B overexpression reduces phosphorylation of the tropomyosin receptor kinase B (TrkB) receptor and the activation of downstream signalling pathways, while PTP1B inhibition increases TrkB signalling. Considering that TrKB implicates PTP1B in the regulation of central brain-derived neurotrophic factor (BDNF) signalling, the study suggested that the beneficial effects of PTP1B inhibition would be exerted by enhancing BDNF/TrkB signalling [106]. Yet another work studies the effects of Roux-en-Y gastric bypass (RYGB) in relation to the hypothalamic suppression of PTP1B. The results obtained therein show that leptin levels were elevated in obese rats and decreased after RYGB. In addition, the expression of the anorexigenic peptide POMC increased and that of the orexigenic peptide NPY decreased in RYGB rats. Furthermore, RYGB surgery decreases PTP1B expression and improves leptin sensitivity through its effects on the leptin signalling cascade [ 107 ]. The importance of this work must be highlighted since RYGB surgery is an effective treatment for obesity and the fact that it decreases the expression of PTP1B and produces an improvement in leptin sensitivity provides further support to the hypothesis. In another study, improvements in leptin and ghrelin levels were found after bariatric surgery which may involve multiple mechanisms, such as a reduction in inflammation and better glycemic control [108]. Elsewhere, research linking leptin to DIO has reported cases in which the elevated hypothalamic expression of PTP1B and TCPTP has been implicated in leptin resistance. Evidence on the subject has found that in POMC neurons, overexpression of the unfolded protein response transcription factor (Xbp1s) decreases the expression of PTP1B and SOCS3, improves leptin and insulin sensitivity, and protects against obesity. Furthermore, the combined deletion of PTP1B and TCPTP in neuronal and glial cells or POMC neurons results in an improvement in leptin sensitivity as well as a decrease in diet-induced obesity [109]. Int. J. Mol. Sci. 2022,23, 5202 16 of 22 altered expression level in an animal model of AD [ 157 ], disrupting leptin signalling. Thus, research should be aimed at the design of inhibitors or related mechanisms to reduce this resistance to leptin. In fact, the design of inhibitors against protein tyrosine phosphatases is possible [ 104 ], and the use of ATR inhibitors to reduce SOCS3 expression has also been suggested [ 103 ]. CNS inflammation or neuroinflammation is an important factor in the development and progression of neurodegenerative diseases [ 29 – 31 ], such as AD, PD, or HD, and inflammation can affect leptin-triggered signalling, leading to leptin resistance [ 158 ]. Thus, the use of anti-inflammatory drugs combined with those that reduce leptin resistance could be useful. Author Contributions: J.A.F.-C. and A.F.-B. wrote the draft, A.P.-P. and G.A. revised the references and text. C.J.-C. made the picture and revised the manuscript, V.S.-M. carried out conceptualization, coordination and revision of the manuscript. All authors have read and agreed to the published version of the manuscript. Funding: PAIDI CTS-151 Junta de Andalucia, Spain. Institutional Review Board Statement: Not applicable. Informed Consent Statement: Not applicable. Data Availability Statement: Not applicable. Conflicts of Interest: The authors declare no conflict of interest. References 1. Bradfield, N.I.; Ames, D. Mild cognitive impairment: Narrative review of taxonomies and systematic review of their prediction of incident Alzheimer’s disease dementia. BJPsych Bull. 2020,44, 67–74. [CrossRef] [PubMed] 2. Chowen, J.A.; Garcia-Segura, L.M. Microglia, neurodegeneration and loss of neuroendocrine control. Prog. Neurobiol. 2020 , 184, 101720. [CrossRef] [PubMed] 3. Moser, V.A.; Christensen, A.; Liu, J.; Zhou, A.; Yagi, S.; Beam, C.R.; Galea, L.; Pike, C.J. Effects of aging, high-fat diet, and testosterone treatment on neural and metabolic outcomes in male brown Norway rats. Neurobiol. Aging 2019 ,73, 145–160. [CrossRef] [PubMed] 4. Forny-Germano, L.; De Felice, F.G.; Do Nascimento Vieira, M.N. The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimer’s Disease. Front. Neurosci. 2019,12, 1027. [CrossRef] [PubMed] 5. Yam, K.Y.; Naninck, E.F.G.; Abbink, M.R.; la Fleur, S.E.; Schipper, L.; van den Beukel, J.C.; Grefhorst, A.; Oosting, A.; van der Beek, E.M.; Lucassen, P.J.; et al. Exposure to chronic early-life stress lastingly alters the adipose tissue, the leptin system and changes the vulnerability to western-style diet later in life in mice. Psychoneuroendocrinology 2017,77, 186–195. [CrossRef] [PubMed] 6. Kiliaan, A.J.; Arnoldussen, I.A.C.; Gustafson, D.R. Adipokines: A link between obesity and dementia? Lancet Neurol. 2014 ,13, 913–923. [CrossRef] 7. Tsai, C.L.; Pan, C.Y.; Chen, F.C.; Huang, T.H.; Tsai, M.C.; Chuang, C.Y. Differences in neurocognitive performance and metabolic and inflammatory indices in male adults with obesity as a function of regular exercise. Exp. Physiol. 2019 ,104, 1650–1660. [CrossRef] [PubMed] 8. Vamanu, E.; Rai, S.N. The Link between Obesity, Microbiota Dysbiosis, and Neurodegenerative Pathogenesis. Diseases 2021 ,9, 45. [CrossRef] 9. Abbott, R.D.; Ross, G.W.; White, L.R.; Nelson, J.S.; Masaki, K.H.; Tanner, C.M.; Curb, J.D.; Blanchette, P.L.; Popper, J.S.; Petrovitch, H. Midlife adiposity and the future risk of Parkinson’s disease. Neurology 2002,59, 1051–1057. [CrossRef] 10. Procaccini, C.; Santopaolo, M.; Faicchia, D.; Colamatteo, A.; Formisano, L.; De Candia, P.; Galgani, M.; De Rosa, V.; Matarese, G. Role of metabolism in neurodegenerative disorders. Metabolism 2016,65, 1376–1390. [CrossRef] 11. Gaba, A.M.; Zhang, K.; Marder, K.; Moskowitz, C.B.; Werner, P.; Boozer, C.N. Energy balance in early-stage Huntington disease. Am. J. Clin. Nutr. 2005,81, 1335–1341. [CrossRef] [PubMed] 12. Beyer, F.; Masouleh, S.K.; Kratzsch, J.; Schroeter, M.L.; Röhr, S.; Riedel-Heller, S.G.; Villringer, A.; Veronica Witte, A. A Metabolic Obesity Profile Is Associated with Decreased Gray Matter Volume in Cognitively Healthy Older Adults. Front. Aging Neurosci. 2019,11, 202. [CrossRef] [PubMed] 13. Hou, Q.; Guan, Y.; Yu, W.; Liu, X.; Wu, L.; Xiao, M.; Lü, Y. Associations between obesity and cognitive impairment in the Chinese elderly: An observational study. Clin. Interv. Aging 2019,14, 367–373. [CrossRef] [PubMed] 14. Hayes, J.P.; Moody, J.N.; Roca, J.G.; Hayes, S.M. Body mass index is associated with smaller medial temporal lobe volume in those at risk for Alzheimer’s disease. NeuroImage Clin. 2020,25, 102156. [CrossRef] 15. Nordestgaard, L.T.; Tybjærg-Hansen, A.; Nordestgaard, B.G.; Frikke-Schmidt, R. Body Mass Index and Risk of Alzheimer’s Disease: A Mendelian Randomization Study of 399,536 Individuals. J. Clin. Endocrinol. Metab. 2017,102, 2310–2320. [CrossRef] Int. J. Mol. Sci. 2022,23, 5202 17 of 22 16. Emmerzaal, T.L.; Kiliaan, A.J.; Gustafson, D.R. 2003–2013: A decade of body mass index, Alzheimer’s disease, and dementia. J. Alzheimers Dis. 2015,43, 739–755. [CrossRef] 17. García-Ptacek, S.; Faxén-Irving, G.; ˇ Cermáková, P.; Eriksdotter, M.; Religa, D. Body mass index in dementia. Eur. J. Clin. Nutr. 2014,68, 1204–1209. [CrossRef] 18. Qizilbash, N.; Gregson, J.; Johnson, M.E.; Pearce, N.; Douglas, I.; Wing, K.; Evans, S.J.W.; Pocock, S.J. BMI and risk of dementia in two million people over two decades: A retrospective cohort study. Lancet Diabetes Endocrinol. 2015,3, 431–436. [CrossRef] 19. Pannacciulli, N.; Del Parigi, A.; Chen, K.; Le, D.S.N.T.; Reiman, E.M.; Tataranni, P.A. Brain abnormalities in human obesity: A voxel-based morphometric study. Neuroimage 2006,31, 1419–1425. [CrossRef] 20. Gunstad, J.; Paul, R.H.; Cohen, R.A.; Tate, D.F.; Spitznagel, M.B.; Gordon, E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr. Psychiatry 2007,48, 57–61. [CrossRef] 21. Raji, C.A.; Ho, A.J.; Parikshak, N.N.; Becker, J.T.; Lopez, O.L.; Kuller, L.H.; Hua, X.; Leow, A.D.; Toga, A.W.; Thompson, P.M. Brain structure and obesity. Hum. Brain Mapp. 2010,31, 353–364. [CrossRef] 22. Marqués-Iturria, I.; Pueyo, R.; Garolera, M.; Segura, B.; Junqué, C.; García-García, I.; JoséSender-Palacios, M.; Vernet-Vernet, M.; Narberhaus, A.; Ariza, M.; et al. Frontal cortical thinning and subcortical volume reductions in early adulthood obesity. Psychiatry Res. 2013,214, 109–115. [CrossRef] 23. Yokum, S.; Ng, J.; Stice, E. Relation of regional gray and white matter volumes to current BMI and future increases in BMI: A prospective MRI study. Int. J. Obes. 2012,36, 656–664. [CrossRef] 24. Debette, S.; Wolf, C.; Lambert, J.C.; Crivello, F.; Soumaré, A.; Zhu, Y.C.; Schilling, S.; Dufouil, C.; Mazoyer, B.; Amouyel, P.; et al. Abdominal obesity and lower gray matter volume: A Mendelian randomization study. Neurobiol. Aging 2014 ,35, 378–386. [CrossRef] 25. Veit, R.; Kullmann, S.; Heni, M.; Machann, J.; Häring, H.U.; Fritsche, A.; Preissl, H. Reduced cortical thickness associated with visceral fat and BMI. NeuroImage Clin. 2014,6, 307–311. [CrossRef] 26. Sharkey, R.J.; Karama, S.; Dagher, A. Overweight is not associated with cortical thickness alterations in children. Front. Neurosci. 2015,9, 24. [CrossRef] 27. Van Boxtel, M.P.J.; Baars, L.; Jolles, J. Obesity, blood pressure and cognitive function: A reply to Waldstein and Katzel. Int. J. Obes. 2007,31, 1186. [CrossRef] 28. Libby, P. Inflammation in atherosclerosis. Nature 2002,420, 868–874. [CrossRef] 29. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006,444, 860–867. [CrossRef] 30. Guillemot-Legris, O.; Muccioli, G.G. Obesity-Induced Neuroinflammation: Beyond the Hypothalamus. Trends Neurosci. 2017 ,40, 237–253. [CrossRef] 31. Cavaliere, G.; Trinchese, G.; Penna, E.; Cimmino, F.; Pirozzi, C.; Lama, A.; Annunziata, C.; Catapano, A.; Mattace Raso, G.; Meli, R.; et al. High-Fat Diet Induces Neuroinflammation and Mitochondrial Impairment in Mice Cerebral Cortex and Synaptic Fraction. Front. Cell. Neurosci. 2019,13, 509. [CrossRef] [PubMed] 32. Crispino, M.; Trinchese, G.; Penna, E.; Cimmino, F.; Catapano, A.; Villano, I.; Perrone-Capano, C.; Mollica, M.P. Interplay between Peripheral and Central Inflammation in Obesity-Promoted Disorders: The Impact on Synaptic Mitochondrial Functions. Int. J. Mol. Sci. 2020,21, 5964. [CrossRef] [PubMed] 33. Pereira, C.F.; Santos, A.E.; Moreira, P.I.; Pereira, A.C.; Sousa, F.J.; Cardoso, S.M.; Cruz, M.T. Is Alzheimer’s disease an inflammasomopathy? Ageing Res. Rev. 2019,56, 100966. [CrossRef] [PubMed] 34. Calsolaro, V.; Edison, P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement. 2016,12, 719–732. [CrossRef] 35. Nuzzo, D.; Picone, P.; Caruana, L.; Vasto, S.; Barera, A.; Caruso, C.; Di Carlo, M. Inflammatory mediators as biomarkers in brain disorders. Inflammation 2014,37, 639–648. [CrossRef] 36. Pistell, P.J.; Morrison, C.D.; Gupta, S.; Knight, A.G.; Keller, J.N.; Ingram, D.K.; Bruce-Keller, A.J. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J. Neuroimmunol. 2010,219, 25–32. [CrossRef] 37. Winocur, G.; Greenwood, C.E. Studies of the effects of high fat diets on cognitive function in a rat model. Neurobiol. Aging 2005 , 26 (Suppl. 1), 46–49. [CrossRef] 38. Sobesky, J.L.; Barrientos, R.M.; De May, H.S.; Thompson, B.M.; Weber, M.D.; Watkins, L.R.; Maier, S.F. High-fat diet consumption disrupts memory and primes elevations in hippocampal IL-1 β , an effect that can be prevented with dietary reversal or IL-1 receptor antagonism. Brain Behav. Immun. 2014,42, 22–32. [CrossRef] 39. Lin, C.I.; Shen, C.F.; Hsu, T.H.; Lin, S.H. A High-Fructose-High-Coconut Oil Diet Induces Dysregulating Expressions of Hippocampal Leptin and Stearoyl-CoA Desaturase, and Spatial Memory Deficits in Rats. Nutrients 2017,9, 619. [CrossRef] 40. Kothari, V.; Luo, Y.; Tornabene, T.; O’Neill, A.M.; Greene, M.W.; Geetha, T.; Babu, J.R. High fat diet induces brain insulin resistance and cognitive impairment in mice. Biochim. Biophys. Acta Mol. Basis Dis. 2017,1863, 499–508. [CrossRef] 41. Ivanova, N.; Liu, Q.; Agca, C.; Agca, Y.; Noble, E.G.; Whitehead, S.N.; Cechetto, D.F. White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer’s disease rat model. J. Neuroinflammation 2020 ,17, 29. [CrossRef] [PubMed] 42. Sah, S.K.; Lee, C.; Jang, J.H.; Park, G.H. Effect of high-fat diet on cognitive impairment in triple-transgenic mice model of Alzheimer’s disease. Biochem. Biophys. Res. Commun. 2017,493, 731–736. [CrossRef] [PubMed] Int. J. Mol. Sci. 2022,23, 5202 18 of 22 43. Frühbeck, G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol. Biol. 2008 ,456, 1–22. [CrossRef] [PubMed] 44. Fietta and Delsante. Focus on Adipokines—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/24640423/ (accessed on 27 April 2022). 45. Effect of Body Mass Index on Serum Leptin Levels—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/23272432/ (accessed on 27 April 2022). 46. Kennedy, A.; Gettys, T.W.; Watson, P.; Wallace, P.; Ganaway, E.; Pan, Q.; Garvey, W.T. The metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J. Clin. Endocrinol. Metab. 1997,82, 1293–1300. [CrossRef] [PubMed] 47. Sinha, M.K.; Ohannesian, J.P.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Magosin, S.; Marco, C.; Caro, J.F. Nocturnal rise of leptin in lean, obese, and non-insulin-dependent diabetes mellitus subjects. J. Clin. Investig. 1996 ,97, 1344–1347. [CrossRef] [PubMed] 48. Wada, N.; Hirako, S.; Takenoya, F.; Kageyama, H.; Okabe, M.; Shioda, S. Leptin and its receptors. J. Chem. Neuroanat. 2014 ,61–62, 191–199. [CrossRef] 49. Hsuchou, H.; Kastin, A.J.; Tu, H.; Markadakis, E.N.; Stone, K.P.; Wang, Y.; Heymsfield, S.B.; Chua, S.S.; Obici, S.; Magrisso, I.J.; et al. Effects of cell-type specific leptin receptor mutation on leptin transport across the BBB. Peptides 2011 ,32, 1392–1399. [CrossRef] 50. Lloret, A.; Monllor, P.; Esteve, D.; Cervera-Ferri, A.; Lloret, M.A. Obesity as a Risk Factor for Alzheimer’s Disease: Implication of Leptin and Glutamate. Front. Neurosci. 2019,13, 508. [CrossRef] 51. Li, S.; Li, X. Leptin in normal physiology and leptin resistance. Sci Bull. 2016,61, 1480–1488. [CrossRef] 52. Arnoldussen, I.A.C.; Kiliaan, A.J.; Gustafson, D.R. Obesity and dementia: Adipokines interact with the brain. Eur. Neuropsychopharmacol. 2014,24, 1982–1999. [CrossRef] 53. Aragonès, G.; Ardid-Ruiz, A.; Ibars, M.; Suárez, M.; Bladé, C. Modulation of leptin resistance by food compounds. Mol. Nutr. Food Res. 2016,60, 1789–1803. [CrossRef] 54. Fujita, Y.; Yamashita, T. The Effects of Leptin on Glial Cells in Neurological Diseases. Front. Neurosci. 2019,13, 828. [CrossRef] 55. Grizzanti, J.; Lee, H.G.; Camins, A.; Pallas, M.; Casadesus, G. The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer’s disease. Nutr. Res. 2016,36, 1305–1315. [CrossRef] 56. Paz-Filho, G.J. The Effects of Leptin Replacement on Neural Plasticity. Neural Plast. 2016,2016, 8528934. [CrossRef] 57. Parimisetty, A.; Dorsemans, A.C.; Awada, R.; Ravanan, P.; Diotel, N.; Lefebvre d’Hellencourt, C. Secret talk between adipose tissue and central nervous system via secreted factors-an emerging frontier in the neurodegenerative research. J. Neuroinflammation 2016,13, 67. [CrossRef] 58. Fruhwürth, S.; Vogel, H.; Schürmann, A.; Williams, K.J. Novel Insights into How Overnutrition Disrupts the Hypothalamic Actions of Leptin. Front. Endocrinol. 2018,9, 89. [CrossRef] 59. McGregor, G.; Harvey, J. Regulation of Hippocampal Synaptic Function by the Metabolic Hormone, Leptin: Implications for Health and Neurodegenerative Disease. Front. Cell. Neurosci. 2018,12, 340. [CrossRef] 60. Pimentel, G.D.; Ganeshan, K.; Carvalheira, J.B.C. Hypothalamic inflammation and the central nervous system control of energy homeostasis. Mol. Cell. Endocrinol. 2014,397, 15–22. [CrossRef] 61. Gruzdeva, O.; Borodkina, D.; Uchasova, E.; Dyleva, Y.; Barbarash, O. Leptin resistance: Underlying mechanisms and diagnosis. Diabetes Metab. Syndr. Obes. 2019,12, 191–198. [CrossRef] [PubMed] 62. McGuire, M.J.; Ishii, M. Leptin Dysfunction and Alzheimer’s Disease: Evidence from Cellular, Animal, and Human Studies. Cell. Mol. Neurobiol. 2016,36, 203–217. [CrossRef] [PubMed] 63. Mejido, D.C.P.; Peny, J.A.; Vieira, M.N.N.; Ferreira, S.T.; De Felice, F.G. Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer’s disease. Neuropharmacology 2020,171, 108115. [CrossRef] [PubMed] 64. Annweiler, C.; Duval, G.T.; Cheng, C.Y.; Wong, T.Y.; Lamoureux, E.L.; Milea, D.; Sabanayagam, C. U-Shaped Relationship between Serum Leptin Concentration and Cognitive Performance in Older Asian Adults. Nutrients 2019,11, 660. [CrossRef] [PubMed] 65. Davis, C.; Mudd, J.; Hawkins, M. Neuroprotective effects of leptin in the context of obesity and metabolic disorders. Neurobiol. Dis. 2014,72 Pt A, 61–71. [CrossRef] 66. McGregor, G.; Harvey, J. Food for thought: Leptin regulation of hippocampal function and its role in Alzheimer’s disease. Neuropharmacology 2018,136, 298–306. [CrossRef] 67. Harrison, L.; Schriever, S.C.; Feuchtinger, A.; Kyriakou, E.; Baumann, P.; Pfuhlmann, K.; Messias, A.C.; Walch, A.; Tschöp, M.H.; Pfluger, P.T. Fluorescent blood-brain barrier tracing shows intact leptin transport in obese mice. Int. J. Obes. 2019 ,43, 1305–1318. [CrossRef] 68. Izquierdo, A.G.; Crujeiras, A.B.; Casanueva, F.F.; Carreira, M.C. Leptin, Obesity, and Leptin Resistance: Where Are We 25 Years Later? Nutrients 2019,11, 2704. [CrossRef] 69. Sáinz, N.; Barrenetxe, J.; Moreno-Aliaga, M.J.; Martínez, J.A. Leptin resistance and diet-induced obesity: Central and peripheral actions of leptin. Metabolism 2015,64, 35–46. [CrossRef] 70. Roujeau, C.; Jockers, R.; Dam, J. New pharmacological perspectives for the leptin receptor in the treatment of obesity. Front. Endocrinol. 2014,5, 167. [CrossRef] Int. J. Mol. Sci. 2022,23, 5202 19 of 22 71. Pérez-Pérez, A.; Sánchez-Jiménez, F.; Vilariño-García, T.; Sánchez-Margalet, V. Role of leptin in inflammation and vice versa. Int. J. Mol. Sci. 2020,21, 5887. [CrossRef] 72. Pérez-Pérez, A.; Vilariño-García, T.; Fernández-Riejos, P.; Martín-González, J.; Segura-Egea, J.J.; Sánchez-Margalet, V. Role of leptin as a link between metabolism and the immune system. Cytokine Growth Factor Rev. 2017,35, 71–84. [CrossRef] 73. Sánchez-Margalet, V.; Martín-Romero, C.; Santos-Alvarez, J.; Goberna, R.; Najib, S.; Gonzalez-Yanes, C. Role of leptin as an immunomodulator of blood mononuclear cells: Mechanisms of action. Clin. Exp. Immunol. 2003 ,133, 11–19. [CrossRef] [PubMed] 74. Sánchez-Margalet, V.; Fernández-Riejos, P.; Najib, S.; Santos-Alvarez, J.; Martín-Romero, C.; Pérez-Pérez, A.; González-Yanes, C. Role of leptin in the activation of immune cells. Mediat. Inflamm. 2010,2010, 568343. [CrossRef] 75. Santos-Alvarez, J.; Goberna, R.; Sánchez-Margalet, V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell. Immunol. 1999,194, 6–11. [CrossRef] [PubMed] 76. Martín-Romero, C.; Santos-Alvarez, J.; Goberna, R.; Sánchez-Margalet, V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell. Immunol. 2000,199, 15–24. [CrossRef] 77. Di Spiezio, A.; Sandin, E.S.; Dore, R.; Müller-Fielitz, H.; Storck, S.E.; Bernau, M.; Mier, W.; Oster, H.; Jöhren, O.; Pietrzik, C.U.; et al. The LepR-mediated leptin transport across brain barriers controls food reward. Mol. Metab. 2018,8, 13–22. [CrossRef] 78. Banks, W.A. The blood-brain barrier as an endocrine tissue. Nat. Rev. Endocrinol. 2019,15, 444–455. [CrossRef] 79. Ardid-Ruiz, A.; Harazin, A.; Barna, L.; Walter, F.R.; Bladé, C.; Suárez, M.; Deli, M.A.; Aragonès, G. The effects of Vitis vinifera L. phenolic compounds on a blood-brain barrier culture model: Expression of leptin receptors and protection against cytokineinduced damage. J. Ethnopharmacol. 2020,247, 112253. [CrossRef] 80. Bartolome, F.; Antequera, D.; Tavares, E.; Pascual, C.; Maldonado, R.; Camins, A.; Carro, E. Obesity and neuroinflammatory phenotype in mice lacking endothelial megalin. J. Neuroinflammation 2017,14, 26. [CrossRef] 81. Rhea, E.M.; Salameh, T.S.; Logsdon, A.F.; Hanson, A.J.; Erickson, M.A.; Banks, W.A. Blood-Brain Barriers in Obesity. AAPS J. 2017 , 19, 921–930. [CrossRef] 82. López, M. Hypothalamic Leptin Resistance: From BBB to BBSome. PLoS Genet. 2016,12, e1005980. [CrossRef] 83. Baumgarner, K.M.; Setti, S.; Diaz, C.; Littlefield, A.; Jones, A.; Kohman, R.A. Diet-induced obesity attenuates cytokine production following an immune challenge. Behav. Brain Res. 2014,267, 33–41. [CrossRef] [PubMed] 84. Son, M.; Oh, S.; Choi, J.; Jang, J.T.; Choi, C.H.; Park, K.Y.; Son, K.H.; Byun, K. Attenuation of Inflammation and Leptin Resistance by Pyrogallol-Phloroglucinol-6,6-Bieckol on in the Brain of Obese Animal Models. Nutrients 2019 ,11, 2773. [CrossRef] [PubMed] 85. Li, J.; Wei, D.; McCrory, M.A.; Szalai, A.J.; Yang, G.; Li, L.; Li, F.; Zha, A.Z. Human C-reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in the CNS. Biochem. J. 2016,473, 1215–1224. [CrossRef] 86. Liu, Z.; Gan, L.; Zhou, Z.; Jin, W.; Sun, C. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology 2015,220, 947–953. [CrossRef] [PubMed] 87. Nakata, M.; Yamamoto, S.; Okada, T.; Gantulga, D.; Okano, H.; Ozawa, K.; Yada, T. IL-10 gene transfer upregulates arcuate POMC and ameliorates hyperphagia, obesity and diabetes by substituting for leptin. Int. J. Obes. 2016,40, 425–433. [CrossRef] 88. Cheng, L.; Hu, T.; Shi, H.; Chen, X.; Wang, H.; Zheng, K.; Huang, X.F.; Yu, Y. DHA reduces hypothalamic inflammation and improves central leptin signaling in mice. Life Sci. 2020,257, 118036. [CrossRef] 89. Wu, Y.; Huang, X.F.; Bell, C.; Yu, Y. Ginsenoside Rb1 improves leptin sensitivity in the prefrontal cortex in obese mice. CNS Neurosci. Ther. 2018,24, 98–107. [CrossRef] 90. Wu, Y.; Yu, Y.; Szabo, A.; Han, M.; Huang, X.F. Central inflammation and leptin resistance are attenuated by ginsenoside Rb1 treatment in obese mice fed a high-fat diet. PLoS ONE 2014,9, e92618. [CrossRef] 91. Jeon, B.T.; Kim, K.E.; Heo, R.W.; Shin, H.J.; Yi, C.; Hah, Y.S.; Kim, W.H.; Lee, S.; Roh, G.S. Myeloid-specific deletion of SIRT1 increases hepatic steatosis and hypothalamic inflammation in mice fed a high-fat diet. Metab. Brain Dis. 2014 ,29, 635–643. [CrossRef] 92. Paz-Filho, G.; Mastronardi, C.A.; Licinio, J. Leptin treatment: Facts and expectations. Metabolism 2015,64, 146–156. [CrossRef] 93. Hosoi, T.; Ozawa, K. Possible Pharmacological Approach Targeting Endoplasmic Reticulum Stress to Ameliorate Leptin Resistance in Obesity. Front. Endocrinol. 2016,7, 59. [CrossRef] 94. Hosoi, T.; Kuwamura, A.; Thon, M.; Tsuchio, K.; El-Hafeez, A.A.A.; Ozawa, K. Possible involvement of 4-hydroxy-2-nonenal in the pathogenesis of leptin resistance in obesity. Am. J. Physiol. Cell Physiol. 2019,316, C641–C648. [CrossRef] 95. Ramírez, S.; Claret, M. Hypothalamic ER stress: A bridge between leptin resistance and obesity. FEBS Lett. 2015 ,589, 1678–1687. [CrossRef] 96. Hakim, F.; Wang, Y.; Carreras, A.; Hirotsu, C.; Zhang, J.; Peris, E.; Gozal, D. Chronic sleep fragmentation during the sleep period induces hypothalamic endoplasmic reticulum stress and PTP1b-mediated leptin resistance in male mice. Sleep 2015 ,38, 31–40. [CrossRef] 97. Yuan, X.W.; Han, S.F.; Zhang, J.W.; Xu, J.Y.; Qin, L.Q. Leucine supplementation improves leptin sensitivity in high-fat diet fed rats. Food Nutr. Res. 2015,59, 27373. [CrossRef] 98. Pedroso, J.A.B.; Silveira, M.A.; Lima, L.B.; Furigo, I.C.; Zampieri, T.T.; Ramos-Lobo, A.M.; Buonfiglio, D.C.; Teixeira, P.D.S.; Frazão, R.; Donato, J. Changes in Leptin Signaling by SOCS3 Modulate Fasting-Induced Hyperphagia and Weight Regain in Mice. Endocrinology 2016,157, 3901–3914. [CrossRef] Int. J. Mol. Sci. 2022,23, 5202 20 of 22 99. Pedroso, J.A.B.; Buonfiglio, D.C.; Cardinali, L.I.; Furigo, I.C.; Ramos-Lobo, A.M.; Tirapegui, J.; Elias, C.F.; Donato, J. Inactivation of SOCS3 in leptin receptor-expressing cells protects mice from diet-induced insulin resistance but does not prevent obesity. Mol. Metab. 2014,3, 608–618. [CrossRef] 100. Heldsinger, A.; Grabauskas, G.; Wu, X.; Zhou, S.; Lu, Y.; Song, I.; Owyang, C. Ghrelin induces leptin resistance by activation of suppressor of cytokine signaling 3 expression in male rats: Implications in satiety regulation. Endocrinology 2014 ,155, 3956–3969. [CrossRef] 101. Piao, L.; Park, J.; Li, Y.; Shin, S.; Shin, S.; Kong, G.; Shrestha, R.; Tran, Q.; Hur, G.M.; Kim, J.L.; et al. SOCS3 and SOCS6 are required for the risperidone-mediated inhibition of insulin and leptin signaling in neuroblastoma cells. Int. J. Mol. Med. 2014 ,33, 1364–1370. [CrossRef] 102. Pedroso, J.A.B.; Ramos-Lobo, A.M.; Donato, J. SOCS3 as a future target to treat metabolic disorders. Hormones 2019 ,18, 127–136. [CrossRef] 103. Ericson, E.; Wennberg Huldt, C.; Strömstedt, M.; Brodin, P. A novel role of the checkpoint kinase ATR in leptin signaling. Mol. Cell. Endocrinol. 2015,412, 257–264. [CrossRef] [PubMed] 104. Dodd, G.T.; Xirouchaki, C.E.; Eramo, M.; Mitchell, C.A.; Andrews, Z.B.; Henry, B.A.; Cowley, M.A.; Tiganis, T. Intranasal Targeting of Hypothalamic PTP1B and TCPTP Reinstates Leptin and Insulin Sensitivity and Promotes Weight Loss in Obesity. Cell Rep. 2019,28, 2905–2922.e5. [CrossRef] [PubMed] 105. Tsou, R.C.; Rak, K.S.; Zimmer, D.J.; Bence, K.K. Improved metabolic phenotype of hypothalamic PTP1B-deficiency is dependent upon the leptin receptor. Mol. Metab. 2014,3, 301–312. [CrossRef] [PubMed] 106. Ozek, C.; Kanoski, S.E.; Zhang, Z.Y.; Grill, H.J.; Bence, K.K. Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling. J. Biol. Chem. 2014 ,289, 31682–31692. [CrossRef] 107. Liu, J.Y.; Mu, S.; Zhang, S.P.; Guo, W.; Li, Q.F.; Xiao, X.Q.; Zhang, J.; Wang, Z.H. Roux-en-Y gastric bypass surgery suppresses hypothalamic PTP1B protein level and alleviates leptin resistance in obese rats. Exp. Ther. Med. 2017 ,14, 2536–2542. [CrossRef] [PubMed] 108. Alosco, M.L.; Spitznagel, M.B.; Strain, G.; Devlin, M.; Cohen, R.; Crosby, R.D.; Mitchell, J.E.; Gunstad, J. Improved serum leptin and ghrelin following bariatric surgery predict better postoperative cognitive function. J. Clin. Neurol. 2015 ,11, 48–56. [CrossRef] 109. Zhang, Z.Y.; Dodd, G.T.; Tiganis, T. Protein Tyrosine Phosphatases in Hypothalamic Insulin and Leptin Signaling. Trends Pharmacol. Sci. 2015,36, 661–674. [CrossRef] 110. Verma, M.; Gupta, S.J.; Chaudhary, A.; Garg, V.K. Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents—A brief review. Bioorg. Chem. 2017,70, 267–283. [CrossRef] [PubMed] 111. Krishnan, N.; Konidaris, K.F.; Gasser, G.; Tonks, N.K. A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models. J. Biol. Chem. 2018 ,293, 1517–1525. [CrossRef] [PubMed] 112. Derkach, K.V.; Zakharova, I.O.; Romanova, I.V.; Zorina, I.I.; Mikhrina, A.L.; Shpakov, A.O. Metabolic parameters and functional state of hypothalamic signaling systems in A Y/a mice with genetic predisposition to obesity and the effect of metformin. Dokl. Biochem. Biophys. 2017,477, 377–381. [CrossRef] [PubMed] 113. Ito, M.; Fukuda, S.; Sakata, S.; Morinaga, H.; Ohta, T. Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. J. Diabetes Res. 2014,2014, 680348. [CrossRef] 114. Ito, Y.; Fukui, M.; Kanda, M.; Morishita, K.; Shoji, Y.; Kitao, T.; Hinoi, E.; Shirahase, H. Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice. J. Pharmacol. Sci. 2018,137, 38–46. [CrossRef] 115. Kaneko, K.; Fu, Y.; Lin, H.Y.; Cordonier, E.L.; Mo, Q.; Gao, Y.; Yao, T.; Naylor, J.; Howard, V.; Saito, K.; et al. Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J. Clin. Investig. 2019,129, 3786–3791. [CrossRef] 116. Hurley, M.M.; Anderson, E.M.; Chen, C.; Maunze, B.; Hess, E.M.; Block, M.E.; Patel, N.; Cooper, Z.; McCoy, R.; Dabra, T.; et al. Acute Blockade of PACAP-Dependent Activity in the Ventromedial Nucleus of the Hypothalamus Disrupts Leptin-Induced Behavioral and Molecular Changes in Rats. Neuroendocrinology 2020,110, 271–281. [CrossRef] 117. Dhar-Mascareno, M.; Ramirez, S.N.; Rozenberg, I.; Rouille, Y.; Kral, J.G.; Mascareno, E.J. Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal. Mol. Endocrinol. 2016,30, 314–324. [CrossRef] 118. Yang, L.; McKnight, G.S. Hypothalamic PKA regulates leptin sensitivity and adiposity. Nat. Commun. 2015,6, 8237. [CrossRef] 119. Sahu, M.; Anamthathmakula, P.; Sahu, A. Phosphodiesterase-3B-cAMP pathway of leptin signalling in the hypothalamus is impaired during the development of diet-induced obesity in FVB/N mice. J. Neuroendocrinol. 2015,27, 293–302. [CrossRef] 120. Christensen, A.; Pike, C.J. APOE genotype affects metabolic and Alzheimer-related outcomes induced by Western diet in female EFAD mice. FASEB J. 2019,33, 4054–4066. [CrossRef] 121. Rai, S.N.; Singh, C.; Singh, A.; Singh, M.P.; Singh, B.K. Mitochondrial Dysfunction: A Potential Therapeutic Target to Treat Alzheimer’s Disease. Mol. Neurobiol. 2020,57, 3075–3088. [CrossRef] 122. Rai, Y.; Anita; Kumari, N.; Singh, S.; Kalra, N.; Soni, R.; Bhatt, A.N. Mild mitochondrial uncoupling protects from ionizing radiation induced cell death by attenuating oxidative stress and mitochondrial damage. Biochim. Biophys. Acta-Bioenerg. 2021 , 1862, 148325. [CrossRef] Int. J. Mol. Sci. 2022,23, 5202 21 of 22 123. Singh, A.K.; Rai, S.N.; Maurya, A.; Mishra, G.; Awasthi, R.; Shakya, A.; Chellappan, D.K.; Dua, K.; Vamanu, E.; Chaudhary, S.K.; et al. Therapeutic Potential of Phytoconstituents in Management of Alzheimer’s Disease. Evid. Based. Complement. Alternat. Med. 2021,2021, 5578574. [CrossRef] 124. Tripathi, P.N.; Srivastava, P.; Sharma, P.; Tripathi, M.K.; Seth, A.; Tripathi, A.; Rai, S.N.; Singh, S.P.; Shrivastava, S.K. Biphenyl-3- oxo-1,2,4-triazine linked piperazine derivatives as potential cholinesterase inhibitors with anti-oxidant property to improve the learning and memory. Bioorg. Chem. 2019,85, 82–96. [CrossRef] 125. Srivastava, P.; Tripathi, P.N.; Sharma, P.; Rai, S.N.; Singh, S.P.; Srivastava, R.K.; Shankar, S.; Shrivastava, S.K. Design and development of some phenyl benzoxazole derivatives as a potent acetylcholinesterase inhibitor with antioxidant property to enhance learning and memory. Eur. J. Med. Chem. 2019,163, 116–135. [CrossRef] 126. Kang, S.; Lee, Y.H.; Lee, J.E. Metabolism-Centric Overview of the Pathogenesis of Alzheimer’s Disease. Yonsei Med. J. 2017 ,58, 479–488. [CrossRef] 127. Folch, J.; Patraca, I.; Martínez, N.; Pedrós, I.; Petrov, D.; Ettcheto, M.; Abad, S.; Marin, M.; Beas-Zarate, C.; Camins, A. The role of leptin in the sporadic form of Alzheimer’s disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. Life Sci. 2015,140, 19–28. [CrossRef] 128. Pedrós, I.; Petrov, D.; Artiach, G.; Abad, S.; Ramon-Duaso, C.; Sureda, F.; Pallàs, M.; Beas-Zarate, C.; Folch, J.; Camins, A. Adipokine pathways are altered in hippocampus of an experimental mouse model of Alzheimer’s disease. J. Nutr. Health Aging 2015,19, 403–412. [CrossRef] [PubMed] 129. Vieira, M.N.N.; Lima-Filho, R.A.S.; De Felice, F.G. Connecting Alzheimer’s disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology 2018,136, 160–171. [CrossRef] [PubMed] 130. Maioli, S.; Lodeiro, M.; Merino-Serrais, P.; Falahati, F.; Khan, W.; Puerta, E.; Codita, A.; Rimondini, R.; Ramirez, M.J.; Simmons, A.; et al. Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer’s disease. Aging Cell 2015 ,14, 122–129. [CrossRef] [PubMed] 131. Bonda, D.J.; Stone, J.G.; Torres, S.L.; Siedlak, S.L.; Perry, G.; Kryscio, R.; Jicha, G.; Casadesus, G.; Smith, M.A.; Zhu, X.; et al. Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance. J. Neurochem. 2014 ,128, 162–172. [CrossRef] [PubMed] 132. Baranowska-Bik, A.; Bik, W.; Styczynska, M.; Chodakowska-Zebrowska, M.; Barcikowska, M.; Wolinska-Witort, E.; Kalisz, M.; Martynska, L.; Baranowska, B. Plasma leptin levels and free leptin index in women with Alzheimer’s disease. Neuropeptides 2015 , 52, 73–78. [CrossRef] [PubMed] 133. Ishii, M.; Iadecola, C. Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology. Biochim. Biophys. Acta 2016,1862, 966–974. [CrossRef] [PubMed] 134. Albala, C.; Angel, B.; Lera, L.; Sanchez, H.; Marquez, C.; Fuentes, P. Low Leptin Availability as a Risk Factor for Dementia in Chilean Older People. Dement. Geriatr. Cogn. Dis. Extra 2016,6, 295–302. [CrossRef] [PubMed] 135. Johnston, J.; Hu, W.; Fardo, D.; Greco, S.; Perry, G.; Montine, T.; Trojanowski, J.; Shaw, L.; Ashford, J.; Tezapsidis, N. Low plasma leptin in cognitively impaired ADNI subjects: Gender differences and diagnostic and therapeutic potential. Curr. Alzheimer Res. 2014,11, 165–174. [CrossRef] [PubMed] 136. Ishii, M.; Wang, G.; Racchumi, G.; Dyke, J.P.; Iadecola, C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J. Neurosci. 2014,34, 9096–9106. [CrossRef] [PubMed] 137. Ülker, M.; Kenangil, G. The Relation of Circulating Levels of Leptin with Cognition in Patients with Alzheimer’s Disease. Noro Psikiyatr. Ars. 2018,55, 211–214. [CrossRef] 138. Teunissen, C.E.; Van Der Flier, W.M.; Scheltens, P.; Duits, A.; Wijnstok, N.; Nijpels, G.; Dekker, J.M.; Blankenstein, R.M.A.; Heijboer, A.C. Serum leptin is not altered nor related to cognitive decline in Alzheimer’s disease. J. Alzheimers Dis. 2015 ,44, 809–813. [CrossRef] 139. Wan, Z.; Mah, D.; Simtchouk, S.; Kluftinger, A.; Little, J.P. Role of amyloid β in the induction of lipolysis and secretion of adipokines from human adipose tissue. Adipocyte 2014,4, 212–216. [CrossRef] 140. Yeh, S.H.H.; Shie, F.S.; Liu, H.K.; Yao, H.H.; Kao, P.C.; Lee, Y.H.; Chen, L.M.; Hsu, S.M.; Chao, L.J.; Wu, K.W.; et al. A high-sucrose diet aggravates Alzheimer’s disease pathology, attenuates hypothalamic leptin signaling, and impairs food-anticipatory activity in APPswe/PS1dE9 mice. Neurobiol. Aging 2020,90, 60–74. [CrossRef] 141. Meakin, P.J.; Jalicy, S.M.; Montagut, G.; Allsop, D.J.P.; Cavellini, D.L.; Irvine, S.W.; McGinley, C.; Liddell, M.K.; McNeilly, A.D.; Parmionova, K.; et al. Bace1-dependent amyloid processing regulates hypothalamic leptin sensitivity in obese mice. Sci. Rep. 2018,8, 55. [CrossRef] 142. Lee, Y.H.; Hsu, H.C.; Kao, P.C.; Shiao, Y.J.; Yeh, S.H.H.; Shie, F.S.; Hsu, S.M.; Yeh, C.W.; Liu, H.K.; Yang, S.B.; et al. Augmented Insulin and Leptin Resistance of High Fat Diet-Fed APPswe/PS1dE9 Transgenic Mice Exacerbate Obesity and Glycemic Dysregulation. Int. J. Mol. Sci. 2018,19, 2333. [CrossRef] 143. Vieira, M.N.N.; Lyra e Silva, N.M.; Ferreira, S.T.; De Felice, F.G. Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer’s Therapy? Front. Aging Neurosci. 2017,9, 7. [CrossRef] [PubMed] 144. Myers, M.G. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog. Horm. Res. 2004 ,59, 287–304. [CrossRef] [PubMed] Int. J. Mol. Sci. 2022,23, 5202 22 of 22 145. Bjørbæk, C.; Elmquist, J.K.; Frantz, J.D.; Shoelson, S.E.; Flier, J.S. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol. Cell 1998,1, 619–625. [CrossRef] 146. Banks, A.S.; Davis, S.M.; Bates, S.H.; Myers, M.G. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 2000,275, 14563–14572. [CrossRef] [PubMed] 147. Gong, Y.; Ishida-Takahashi, R.; Villanueva, E.C.; Fingar, D.C.; Münzberg, H.; Myers, M.G. The long form of the leptin receptor regulates STAT5 and ribosomal protein S6 via alternate mechanisms. J. Biol. Chem. 2007 ,282, 31019–31027. [CrossRef] [PubMed] 148. Carpenter, L.R.; Farruggella, T.J.; Symes, A.; Karow, M.L.; Yancopoulos, G.D.; Stahl, N. Enhancing leptin response by preventing SH2-containing phosphatase 2 interaction with Ob receptor. Proc. Natl. Acad. Sci. USA 1998 ,95, 6061–6066. [CrossRef] [PubMed] 149. Tang, Z.; Bereczki, E.; Zhang, H.; Wang, S.; Li, C.; Ji, X.; Branca, R.M.; Lehtiö, J.; Guan, Z.; Filipcik, P.; et al. Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: Implication for Alzheimer disease. J. Biol. Chem. 2013 ,288, 15556–15570. [CrossRef] 150. Wang, L.; Cheng, S.; Yin, Z.; Xu, C.; Lu, S.; Hou, J.; Yu, T.; Zhu, X.; Zou, X.; Peng, Y.; et al. Conditional inactivation of Akt three isoforms causes tau hyperphosphorylation in the brain. Mol. Neurodegener. 2015,10, 33. [CrossRef] 151. Jiang, J.; Wang, Z.H.; Qu, M.; Gao, D.; Liu, X.P.; Zhu, L.Q.; Wang, J.Z. Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.Sci. Rep. 2015,5, srep11765. [CrossRef] 152. Uotani, S.; Abe, T.; Yamaguchi, Y. Leptin activates AMP-activated protein kinase in hepatic cells via a JAK2-dependent pathway. Biochem. Biophys. Res. Commun. 2006,351, 171–175. [CrossRef] 153. Greco, S.J.; Hamzelou, A.; Johnston, J.M.; Smith, M.A.; Ashford, J.W.; Tezapsidis, N. Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and β -amyloid in neurons. Biochem. Biophys. Res. Commun. 2011 , 414, 170–174. [CrossRef] 154. Wang, R.; Li, J.J.; Diao, S.; Kwak, Y.D.; Liu, L.; Zhi, L.; Büeler, H.; Bhat, N.R.; Williams, R.W.; Park, E.A.; et al. Metabolic stress modulates Alzheimer’s β -secretase gene transcription via SIRT1-PPAR γ -PGC-1 in neurons. Cell Metab. 2013 ,17, 685–694. [CrossRef] 155. Marwarha, G.; Raza, S.; Meiers, C.; Ghribi, O. Leptin attenuates BACE1 expression and amyloidβ genesis via the activation of SIRT1 signaling pathway. Biochim. Biophys. Acta 2014,1842, 1587–1595. [CrossRef] 156. Cook, W.S.; Unger, R.H. Protein tyrosine phosphatase 1B: A potential leptin resistance factor of obesity. Dev. Cell 2002 ,2, 385–387. [CrossRef] 157. King, A.; Brain, A.; Hanson, K.; Dittmann, J.; Vickers, J.; Fernandez-Martos, C. Disruption of leptin signalling in a mouse model of Alzheimer’s disease. Metab. Brain Dis. 2018,33, 1097–1110. [CrossRef] 158. Dragano, N.R.V.; Haddad-Tovolli, R.; Velloso, L.A. Leptin, Neuroinflammation and Obesity. Front. Horm. Res. 2017 ,48, 84–96. [CrossRef]